What if researchers have an Initial Review application for a non-COVID-19 study currently under review?

Last updated: 4.14.20

As of April 14, 2020, all face-to-face study visits must be temporarily halted until at least June 30, 2020. Exceptions to this hiatus are therapeutic studies involving drugs or devices, or other research activities that are critical to the health/safety of patients or study participants. These studies may continue using face-to-face interactions. Therefore, if a researcher has a therapeutic study currently under review, no revisions should be necessary in order to proceed with plans for face-to-face study visits, however, there may be limitations on study activation based on resources available in the CRU, the Pharmaceutical Research Center (PRC), and other hospital resources.

If the study is non-therapeutic and currently includes face-to-face study visits, researchers will need to choose one of the of the following options: